000			03870nam a22006137a 4500
008			190827s20192019 xxu||||| |||| 00| 0 eng d
022			_a1876-4789
024			_a10.1016/j.jacl.2019.07.004 [doi]
024			_aS1933-2874(19)30236-3 [pii]
040			_aOvid MEDLINE(R)
099			_a31427271
245			_aThe economic burden of hypertriglyceridemia among US adults with diabetes or atherosclerotic cardiovascular disease on statin therapy.
251			_aJournal of Clinical Lipidology. 13(5):754-761, 2019 Sep - Oct.
252			_aJ. clin. lipidol.. 13(5):754-761, 2019 Sep - Oct.
252			_zJ. clin. lipidol.. 2019 Jul 20
253			_aJournal of clinical lipidology
260			_c2019
260			_fFY2020
265			_saheadofprint
265			_sppublish
266			_d2019-08-27
268			_aJournal of Clinical Lipidology. 2019 Jul 20
520			_aBACKGROUND: Hypertriglyceridemia (HTG) is associated with increased cardiovascular disease (CVD) risk. However, the cost burden of HTG-related CVD in high-risk US adults on statins has not been well characterized.
520			_aCONCLUSION: In US adults on statins and at high risk for CVD, the health care costs associated with HTG are substantial.
520			_aCopyright (c) 2019 National Lipid Association. Published by Elsevier Inc. All rights reserved.
520			_aMETHODS: We estimated population sizes and annual health care costs among US adults aged >=45 years with diabetes or CVD taking statin therapy with normal triglycerides (TGs) defined as TG < 150 mg/dL compared with those with HTG defined as TG >= 150 mg/dL. Population sizes were estimated from the 2007-2014 National Health and Nutrition Examination Surveys. Adjusted mean total annual health care costs in 2015 US dollars were estimated using the Optum Research Database. The annual total health care cost burden was estimated by multiplying the population size by the mean annual total incremental health care costs overall and within subgroups.
520			_aOBJECTIVE: We estimated the HTG-related health care cost burden among US adults with CVD or diabetes taking statin therapy.
520			_aRESULTS: There were 6.2 (95% confidence interval [CI], 5.4 - 7.1) million and 12.0 (95% CI, 11.1 - 12.9) million US adults aged >=45 years with diabetes and/or CVD on statin therapy with TG >= 150 mg/dL and TG < 150 mg/dL, respectively. The mean adjusted incremental total one-year health care costs in adults with TG >= 150 mg/dL compared with those with TG < 150 mg/dL was _1730 (95% CI, _1160 - _2320). This leads to a projected annual incremental cost burden associated with HTG in patients with diabetes or CVD on statins of _10.7 billion (95% CI, _6.8 B - _14.6 B).
546			_aEnglish
650			_a*Atherosclerosis/dt [Drug Therapy]
650			_a*Atherosclerosis/ec [Economics]
650			_a*Cardiovascular Diseases/ec [Economics]
650			_a*Cost of Illness
650			_a*Diabetes Mellitus/ec [Economics]
650			_a*Hydroxymethylglutaryl-CoA Reductase Inhibitors/ec [Economics]
650			_a*Hydroxymethylglutaryl-CoA Reductase Inhibitors/tu [Therapeutic Use]
650			_a*Hypertriglyceridemia/ec [Economics]
650			_aAdult
650			_aAged
650			_aFemale
650			_aHealth Care Costs
650			_aHumans
650			_aMale
650			_aMiddle Aged
650			_aUnited States/ep [Epidemiology]
651			_aMedStar Heart & Vascular Institute
657			_aJournal Article
700			_aCase, Brian C
700			_aKolm, Paul
700			_aWeintraub, William S
790			_aBress AP, Case BC, Fan W, Granowitz CB, Herrick JS, Hull M, Kolm P, Philip S, Toth PP, Weintraub WS, Wong ND
856			_uhttps://dx.doi.org/10.1016/j.jacl.2019.07.004 _zhttps://dx.doi.org/10.1016/j.jacl.2019.07.004
942			_cART _dArticle
999			_c4541 _d4541